Attendee search 

Macquarie is an Austrian bank company, operating in 31 Markets

CP pharmaceutical group is a leading healthcare player in China. Stock listed in H. K. since 2000.

MNC

A public pharmaceutical company

HitGen is a rapidly growing biotech company with headquarter and main research facility based in Chengdu, China and with a subsidiary in the United States. HitGen has established an industry-leading platform for early-stage drug discovery research centred on the design, synthesis and screening of DNA encoded chemical libraries (DELs).

HitGen’s DELs cover more than 500 billion novel, diverse molecules from different types of chemical libraries, including drug-like/lead-like small molecules, macrocycles, molecules with electrophiles (co-valent binding), protein degraders, molecular fragments, etc,. These compounds are members of DELs synthesized from many hundreds of distinct chemical scaffolds, designed with tractable chemistry, and yielded proven results for the discovery of small molecule leads against precedented and unprecedented classes of biological targets.

In order to support the exploitation of DEL screening output, HitGen has also built structural biology, medicinal chemistry, in vitro and in vivo biology capabilities to support our partner’s drug discovery research projects.

HitGen is collaborating with pharmaceutical, biotech, and chemical companies, foundations and research institutes in North America, Europe, Asia and Africa to discover and develop approaches for novel medicines and other solutions.

HitGen's novel small molecule inhibitor for Class I/IIb HDAC, HG146, is in Phase I clinical trials for Multiple Myeloma. Another new class of second generation TRK/ROS1 inhibitor, HG030, has obtained clinical approval from NMPA. HitGen’s preclinical portfolio includes small molecule IL17A inhibitor and non-nucleoside STING agonist.

http://chinabio-partnering.com/events/CBPF2020/en/home

Zhongyuan Yuzi is a provincial investment company and a province-managed state-owned corporation, the establishment of which is approved by Henan provincial government, with the function of serving the strategy and market operation and the role in safeguarding the investment of provincial infrastructure projects,cultivating and guiding the strategic emerging industries, leading and inciting the social investments.

Currently, we are looking for leading pharmaceutical companies as long-term financial or strategic investment partnerships.

河南省骨干企业。先后发起设立了3000亿元规模的河南省新型城镇化发展基金、1000亿元规模的“一带一路（河南）发展基金”、 1000亿元规模的全省现代服务业基金、50亿元规模的PPP开发性基金。

截至2019年12月底，豫资控股集团注册资金100亿元，合并总资产2734.9亿，净资产845.57亿。豫资控股集团子公司及孙公司（并表子公司）共计67家，其中二级子公司11家，三级子公司56家。国内评级AAA、国际评级A2。

Listed in China Growth Board, WolwoPharma is the biggest allergen drug manufacturer in China
and the largest allergen preparation supplier in Asia.

Bionus Biotechnology was established in 2018， with an angel investment of a Finnish Company Currently we have 15 team members, 10 full-time, and 100% master's degree or above. Bionus has in-depth cooperation with the Karolinska Institute , Tokyo Medical and Dental University and Machine Learning Tokyo, the core members of the team had the background of Nobel Prize laureate in 2018, Mr. Tasuku Honjo.

The team currently covers 2 major layouts (AI-assisted small molecule chemical drug screening and creation of new peptide vaccines), 6 types of diseases, 12 pipelines, of which the fastest is a First in class:
At present, we are looking forward to the project financing of the anti-tumor CTLA-4 novel peptide vaccine of 10 million yuan. The main United Statesges is to complete the vaccine safety evaluation before the IND. The current anti-tumor CTLA-4 new peptide vaccine, preclinical trials have been nearly completed, and the effect is obvious. We are confident to make new technological innovations in tumor vaccines.

Heathcare PE fund